Creative Bioarray Has Developed Cell Immortalization Services to Support Potential Drug Development
Jul 27, 2022
New York City, New York Jul 27, 2022 (Issuewire.com) - Creative Bioarray, one of the leading biotechnology companies focuses on developing high-quality products and services in order to accelerate research in the field of biopharma, drug development, and life science industry. Recently, Creative Bioarray announced the release of its cell immortalization services and kits that can be applied to extend the replicative capacity of target cells and further support potential drug development.
Based on an experienced team of scientists and a well-designed technology platform, Creative Bioarray provides cell immortalization services and has been able to successfully immortalize cells from any species and any tissue with functions desired by customers. As a leading manufacturer of primary cells, stem cells, and immune cells, Creative Bioarray can provide starting material from any species and any tissue. In addition, the professional team is capable to establish an isolation protocol and then conducting custom isolation for the clients.
Currently, Creative Bioarray has developed several HT® Cell Immortalization Kits for immortalizing mammalian cells in culture:
Viral genes, such as EBV, HPV-16 E6/7 genes, and SV40 T antigen, are used to induce immortalization. In most cases, viral genes are immortalized by inactivating tumor suppressor genes (p53, Rb, etc.) that can induce a replicative senescence state in cells.
SV40 T antigen has been shown to be the simplest and most reliable reagent for transforming many different cell types in culture, and the mechanism of SV40 T antigen in cell immortalization has been intensively studied. Recent studies have also shown that the SV40 T antigen can induce telomerase activity in infected cells.
A recently discovered method of cell immortalization is through the expression of TERT, especially for cells that are most affected by telomere length. This protein is inactive in most somatic cells, but when hTERT is exogenously expressed, cells are able to maintain sufficient telomere length to avoid replicative senescence. Analysis of several telomerase-immortalized cell lines has confirmed that cells maintain a stable genotype and retain key phenotypic markers.
Co-expression of the hTERT catalytic subunit with p53 or RB siRNA immortalizes primary human ovarian epithelial cells, providing a more realistic normal cell model with well-defined genetic background.
"Creative Bioarray can provide you with an integrated platform of immortalized human cell lines to meet the needs of any related research project." said Hannah Cole, the marketing director of Creative Bioarray, she also added, "Our service team can work with you to develop and execute flexible custom-designed experiments to meet your unique needs and goals."
About Creative Bioarray
Creative Bioarray is dedicated to offering customers innovative biotechnology products and services for research use to greatly enhance and drive innovation and standards in science. As a well-recognized industry leader with more than 10 years of experience and in-house expert support, Creative Bioarray has already countenanced research all around the world.
Media Contact
Hannah Cole
6313868241
Shirley, NY 11967, USA
Source :Creative Bioarray
This article was originally published by IssueWire. Read the original article here.
More News
What to think about when buying travel insurance
Consumer expert Harry Kind walks through what to do when buying travel insurance.
Abortion Pills, Vaccines and Food Safety: F.D.A. Nominee Heidi Overton Faces Senate Confirmation Hearing
Dr. Heidi Overton has called mifepristone “dangerous to women.” As a White House aide, she worked to reduce the number of vaccines recommended for children.
The ‘Monster’ Behind Russia’s Global Effort to Evade Western Sanctions
A Moscow firm uses shell companies and cryptocurrency to launder money, and a custom app to forge trade records, to help Russia bypass sweeping financial restrictions.
Europe's car makers are in crisis. Will the threat of war rescue them?
Auto executives across Europe hope rearmament can help them flex their industrial muscles once more.
Court Blocks Trump’s White House Ban on CNN, MS NOW and Politico
Judge Timothy J. Kelly issued a temporary restraining order and told the White House to immediately restore the press credentials for the employees of the three news outlets.
Food banks 'in crisis' amid fears some may have to close
According to the Trussell Trust, an anti-poverty charity, some food banks are having pay for 30-50% of the food they are supplying.
Rising fuel costs hitting businesses and customers
Business owners say higher fuel costs are creating challenges on several fronts.
Rise in 'commuter students' due to living costs
Some young people are staying at home while attending university as they cannot afford to move.
Elizabeth Holmes to Transfer to Halfway House in August 2027
The founder of the blood-testing start-up Theranos was sentenced to 11 years in prison for fraud and had been serving time at a minimum-security federal prison in Texas.
Virginia logger amazed by China
When the CEO of a small logging company in the U.S. state of Virginia decided to visit China to see his buyer's operation first-hand, he was amazed, not just by the woodworking factory, but China itself.
They were labelled 'pervert glasses'. Will a camera-free version transform their image?
Meta has unveiled audio-only smart glasses, with some questioning whether it is a response to the backlash over privacy.
Epstein’s Accountant and Lawyer Are Said to Be Under Federal Investigation
Lawyers for Darren Indyke and Richard Kahn said their clients were “confident that any investigation will reveal that they were not involved in any of Epstein’s crimes.”
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.